Member Info for Abouttime

I just bought 30k so . Some buys showing as sells, nothing new

142 to buy. People selling at 138. But this could go to 1.55 today. Then buy back in and loose, doesn't make sense.

Big day today.

Big day tomorrow

My 26k buy showing as a sell.

Rns Monday, hopefully good news

Can see this dropping to .76

Buy back in. Its a sea of blue buys

Get in quickly

Buying in at 134

Showcased the potential of its technology, with the MicroBlate Flex being used in a world-first combined procedure at the Royal Brompton Hospital to treat a cancerous lung nodule using a robotic platform.

Despite the business growth, Creo said it had maintained disciplined cost control, contributing to a reduced operating loss for the financial year ended 31 December 2023.

The company said it remained on track to achieve cash flow break-even by 2025.

“The transition from a small medtech start-up, to where the company is now, is testament to not only the quality of the company's technology and products, but also to its leadership, of which you have been an integral part,” the incoming chair Kevin Crofton told the meeting.

“With a strong international presence, a growing user base and world-class partners, Creo Medical is now well positioned for accelerated growth.

“During my recruitment process, I have got to know many members of the talented Creo team, and I am looking forward to getting started and working with them to continue our upwards clinical and commercial trajectory

Creo Medical Group PLC (AIM:CREO) and Intuitive Surgical Inc (NASDAQ:ISRG, ETR:IUI1) have expanded their collaboration to enhance lung cancer treatments across the UK and Europe.

This initiative broadens the scope of an agreement that combines diagnostics and treatment in a single procedure using advanced medical technology.

It combines Intuitive's robotic lung biopsy system with Creo's MicroBlate Flex device, designed for the precise destruction of lung tumours using microwave energy, a technique known as ablation

40 next week

Buy,, news soon.

Shares in Creo Medical Group PLC (AIM:CREO), a company specialising in surgical endoscopy and advanced energy licensing, are rated by Deutsche Bank as 'buy' up to 80p.

In a short update in the wake of full-year results, the German outfit flagged as its key highlight the approval and launch of the Speedboat UltraSlim, which improves compatibility with a broader range of endoscopes. This development is expected to enhance the company's market position and drive future growth.

According to DB, the numbers were all in line with expectations. Sales grew by 13% to £30.8 million, while core technology revenues, including the Speedboat device, increased significantly from £0.9 million in FY22 to £2.3 million in FY23. Combined licensing and core technology sales amounted to £4 million. Consumables sales grew by 8% to £26.8 million. Creo Medical ended the year with a net cash position of £18.5 million.

In afternoon trading the stock was up 1.3% at 36.98p.

18 millions pounds. Made, predicted

Should have some news soon. Then 18p

L@@k 10 million buy

Loads of Directors buying now, a good sign. Confidence in the company as its making progress and profits.

Bitcoin going up. But the hashrate will slow down, profit will half unless they buy more miming rigs.